Childhood onset systemic lupus erythematosus: How is it different from adult SLE?

International Journal of Rheumatic Diseases

Volumn 18, Issue 2, 2015, Pages 182-191

  Aggarwal, Amita ^a   Srivastava, Puja ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Autoantibodies; Complications; Nephritis; Neuropsychiatric; Pediatric; Systemic lupus erythematosus

Indexed keywords

AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; MEPREDNISONE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB;

ADOLESCENCE; ADULT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; GROUPS BY AGE; HUMAN; LIFESPAN; NEPHRITIS; PATHOGENESIS; PHYSICIAN; PRIORITY JOURNAL; SOCIAL NEEDS; STEROID THERAPY; SURVIVAL TIME; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT OUTCOME; ADOLESCENT; AGE; COMPARATIVE STUDY; DISEASE COURSE; DOSE RESPONSE; FEMALE; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; NEEDS ASSESSMENT; ONSET AGE; PATHOPHYSIOLOGY; PHYSIOLOGIC MONITORING; PROCEDURES; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

ADOLESCENT; ADULT; AGE FACTORS; AGE OF ONSET; CHILD; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MONITORING, PHYSIOLOGIC; NEEDS ASSESSMENT; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84927911087     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/1756-185X.12419     Document Type: Article

References (82)

1. Kamphuis S, Silverman ED (2010) Prevalence and burden of pediatric-onset systemic lupus erythematosus. Nat Rev Rheumatol 6 (9), 538-46.
2. Sag E, Tartaglione A, Batu ED et al. (2014) Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. Clin Exp Rheumatol 32 (3), 440-4.
3. Hiraki LT, Benseler SM, Tyrrell PN, Harvey E, Hebert D, Silverman ED (2009) Ethnic differences in pediatric systemic lupus erythematosus. J Rheumatol 36 (11), 2539-46.
4. Huang JL, Yao TC, See LC (2004) Prevalence of pediatric systemic lupus erythematosus and juvenile chronic arthritis in a Chinese population: a nation-wide prospective population-based study in Taiwan. Clin Exp Rheumatol 22 (6), 776-80.
5. Tucker LB, Uribe AG, Fernandez M et al. (2008) Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multi-ethnic US cohort (LUMINA LVII). Lupus 17 (4), 314-22.
6. Miettunen PM, Ortiz-Alvarez O, Petty RE et al. (2004) Gender and ethnic origin have no effect on long-term outcome of childhood-onset systemic lupus erythematosus. J Rheumatol 31 (8), 1650-4.
7. Levy DM, Peschken CA, Tucker LB et al. (2013) Influence of ethnicity on childhood-onset systemic lupus erythematosus: results from a multiethnic multicenter Canadian cohort. Arthritis Care Res (Hoboken) 65, 152-60.
8. Malleson PN, Fung MY, Rosenberg AM (1996) The incidence of pediatric rheumatic diseases: results from the Canadian Pediatric Rheumatology Association Disease Registry. J Rheumatol 23 (11), 1981-7.
9. Pons-Estel GJ, Alarcon GS, Scofield L, Reinib L, Cooper GS (2009) Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39 (4), 257-68.
10. Yeh KW, Yu CH, Chan PC, Horng JT, Huang JL (2013) Burden of systemic lupus erythematosus in Taiwan: a population-based survey. Rheumatol Int 33 (7), 1805-11.
11. Rönnblom L, Eloranta ML (2013) The interferon signature in autoimmune diseases. Curr Opin Rheumatol 25 (2), 248-53.
12. Graham RR, Kozyrev SV, Baechler EC et al. (2006) A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. Nat Genet 38 (5), 550-5.
13. Rullo OJ, Woo JM, Wu H et al. (2010) Association of IRF5 polymorphisms with activation of the interferon alpha pathway. Ann Rheum Dis 69 (3), 611-7.
14. Bauer JW, Petri M, Batliwalla FM et al. (2009) Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study. Arthritis Rheum 60 (10), 3098-107.
15. Postal M, Sinicato NA, Pelicari KO, Marini R, Lavras Costallat LT, Appenzeller S (2012) Clinical and serological manifestations associated with interferon-a levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo) 67 (2), 157-62.
16. Yoo DH (2010) Anticytokine therapy in systemic lupus erythematosus. Lupus 19, 1460-7.
17. Lashine YA, Seoudi AM, Salah S, Abdelaziz AI (2011) Expression signature of microRNA-181-a reveals its crucial role in the pathogenesis of paediatric systemic lupus erythematosus. Clin Exp Rheumatol 29 (2), 351-7.
18. Tang Y, Luo X, Cui H et al. (2009) MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signalling proteins. Arthritis Rheum 60 (4), 1065-75.
19. Pickering MC, Walport MJ (2000) Links between complement abnormalities and systemic lupus erythematosus. Rheumatology (Oxford) 39 (2), 133-41.
20. Belot A, Cimaz R (2012) Monogenic forms of systemic lupus erythematosus: new insights into SLE pathogenesis. Pediatr Rheumatol Online J 10 (1), 21.
21. Webb R, Kelly JA, Somers EC et al. (2011) Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients. Ann Rheum Dis 70 (1), 151-6.
22. Jacob CO, Reiff A, Armstrong DL et al. (2007) Identification of novel susceptibility genes in childhood-onset systemic lupus erythematosus using a uniquely designed candidate gene pathway platform. Arthritis Rheum 56 (12), 4164-73.
23. Armstrong DL, Reiff A, Myones BL et al. (2009) Identification of new SLE-associated genes with a two-step Bayesian study design. Genes Immun 10 (5), 446-56.
24. Jasmin R, Sockalingam S, Cheah TE, Goh KJ (2013) Systemic lupus erythematosus in the multiethnic Malaysian population: disease expression and ethnic differences revisited. Lupus 22 (9), 967-71.
25. Livingston B, Bonner A, Pope J (2011) Differences in clinical manifestations between childhood -onset lupus and adult-onset lupus: a meta analysis. Lupus 20 (13), 1345-55.
26. Hui-Yuen JS, Imundo LF, Avitabile C, Kahn PJ, Eichenfield AH, Levy DM (2011) Early versus later onset childhood-onset systemic lupus erythematosus: clinical features, treatment and outcome. Lupus 20 (9), 952-9.
27. Yeh TT, Yang YH, Lin YT, Lu CS, Chiang BL (2007) Cardiopulmonary involvement in pediatric systemic lupus erythematosus: a twenty-year retrospective analysis. J Microbiol Immunol Infect 40 (6), 525-31.
28. Richer O, Ulinski T, Lemelle I et al. (2007) Abdominal manifestations in childhood-onset systemic lupus erythematosus. Ann Rheum Dis 66 (2), 174-8.
29. Huang JL, Yeh KW, Yao TC et al. (2010) Pediatric lupus in Asia. Lupus 19 (12), 1414-8.
30. Mak A, Mok CC, Chu WP, To CH, Wong SN, Au TC (2007) Renal damage in systemic lupus erythematosus: a comparative analysis of different age groups. Lupus 16 (1), 28-34.
31. Wu JY, Yeh KW, Huang JL (2014) Early predictors of outcomes in pediatric lupus nephritis: focus on proliferative lesions. Semin Arthritis Rheum 43 (4), 513-20.
32. Lee PY, Yeh KW, Yao TC, Lee WI, Lin YJ, Huang JL (2013) The outcome of patients with renal involvement in pediatric-onset systemic lupus erythematosus-a 20-year experience in Asia. Lupus 22 (14), 1534-40.
33. Vachvanichsanong P, Dissaneewate P, McNeil E (2011) Twenty-two years' experience with childhood-onset SLE in a developing country: are outcomes similar to developed countries? Arch Dis Child 96 (1), 44-9.
34. Moroni G, Tantardini F, Gallelli B et al. (2005) The long-term prognosis of renal transplantation in patients with lupus nephritis. Am J Kidney Dis 45 (5), 903-11.
35. Benseler SM, Silverman ED (2007) Neuropsychiatric involvement in pediatric systemic lupus erythematosus. Lupus 16 (8), 564-71.
36. Hanly JG, Urowitz MB, Sanchez-Guerrero J et al. (2007) Neuropsychiatric events at the time of diagnosis of systemic lupus erythematosus: an international inception cohort study. Arthritis Rheum 56 (1), 265-73.
37. Muscal E, Brey RL (2010) Neurological manifestations of systemic lupus erythematosus in children and adults. Neurol Clin 28 (1), 61-73.
38. Hoffman IE, Lauwerys BR, De Keyser F et al. (2009) Juvenile-onset systemic lupus erythematosus: different clinical and serological pattern than adult-onset systemic lupus erythematosus. Ann Rheum Dis 68 (3), 412-5.
39. Ramirez Gomez LA, Uribe Uribe O, Osio Uribe O et al. (2008) Childhood systemic lupus erythematosus in Latin America. The GLADEL experience in 230 children. Lupus 17 (6), 596-04.
40. Yu HH, Wang LC, Lee JH, Lee CC, Yang YH, Chiang BL (2007) Lymphopenia is associated with neuropsychiatric manifestations and disease activity in paediatric systemic lupus erythematosus patients. Rheumatology (Oxford) 46, 1492-4.
41. Hazzan R, Mukamel M, Yacobovich J, Yaniv I, Tamary H (2006) Risk factors for future development of systemic lupus erythematosus in children with idiopathic thrombocytopenic purpura. Pediatr Blood Cancer 47 (Suppl. 5), 657-9.
42. Brunner HI, Freedman M, Silverman ED (1999) Close relationship between systemic lupus erythematosus and thrombotic thrombocytopenic purpura in childhood. Arthritis Rheum 42 (11), 2346-55.
43. Hollander MC, Sage JM, Greenler AJ et al. (2013) International consensus for provisions of quality-driven care in childhood-onset systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65 (9), 1416-23.
44. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69 (1), 20-8.
45. Tsakonas E, Joseph L, Esdaile JM et al. (1998) A long-term study of Hydroxyl-chloroquine withdrawal on exacerbations in systemic lupus erythematosus. The Canadian Hydroxychloroquine Study Group. Lupus 7 (2), 80-5.
46. Mina R, von Scheven E, Ardoin SP et al. (2012) Consensus treatment plans for induction therapy of newly diagnosed proliferative lupus nephritis in juvenile systemic lupus erythematosus. Arthritis Care Res (Hoboken) 64 (3), 375-83.
47. Ginzler EM, Dooley MA, Aranow C et al. (2005) Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 353 (21), 2219-28.
48. Sundel R, Solomons N, Lisk L (2012) Efficacy of mycophenolate mofetil in adolescent patients with lupus nephritis: evidence from a two-phase, prospective randomized trial. Lupus 21 (13), 1433-43.
49. Dooley MA, Jayne D, Ginzler EM et al. (2011) Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl J Med 365 (20), 1886-95.
50. Houssiau FA, Vasconcelos C, D'Cruz D et al. (2002) Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46 (8), 2121-31.
51. Bertsias GK, Tektonidou M, Amoura Z et al. (2012) Joint European League Against Rheumatism and European RenalAssociation-European Dialysis and Transplant Association (EULAR/ERA-EDTA)recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis 71 (11), 1771-82.
52. Kumar S, Benseler SM, Kirby-Allen M, Silverman ED (2009) B-cell depletion for autoimmune thrombocytopenia and autoimmune hemolytic anemia in pediatric systemic lupus erythematosus. Pediatrics 123, e159-63.
53. Terrier B, Amoura Z, Ravaud P et al. (2010) Safety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum 62 (8), 2458-66.
54. Merrill JT, Neuwelt CM, Wallace DJ et al. (2010) Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, doublind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 62 (1), 222-33.
55. Furie R, Petri M, Zamani O et al. (2011) A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63 (12), 3918-30.
56. Hui-Yuen JS, Bermudez-Santiago LM, Isgro J et al. (2014) Favorable response to belimumab in childhood-onset systemic lupus erythematosus. Arthritis Rheumatol 66 (Suppl. 11), S37.
57. Silva CA, Aikawa NE, Bonfa E (2013) Vaccinations in juvenile chronic inflammatory diseases: an update. Nat Rev Rheumatol 9 (9), 532-43.
58. Heijstek MW, Ott de Bruin LM, Bijl M et al. (2011) EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 70 (10), 1704-12.
59. Pneumococcal Vaccination Recommendations for Children and Adults by Age and/or Risk Factor. Available at: www.immunize.org/catg.d/p2019.pdf.
60. Chambers SA, Allen E, Rahman A, Isenberg D (2009) Damage and mortality in a group of British patients with systemic lupus erythematosus followed up for over 10 years. Rheumatology (Oxford) 48 (6), 673-5.
61. Hersh AO, Trupin L, Yazdany J et al. (2010) Childhood-onset disease as a predictor of mortality in an adult cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62 (8), 1152-9.
62. Chen YM, Lin CH, Chen HH et al. (2014) Onset age affects mortality and renal outcome of female systemic lupus erythematosus patients: a nationwide population-based study in Taiwan. Rheumatology (Oxford) 53 (1), 180-5.
63. Urowitz MB, Gladman D, Ibanez D et al. (2010) Atherosclerotic vascular events in a multinational inception cohort of systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62 (6), 881-7.
64. Bernatsky S, Boivin JF, Joseph L et al. (2005) An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 52 (5), 1481-90.
65. Perez MD, Abrams SA, Loddeke L, Shypailo R, Ellis KJ (2000) Effects of rheumatic disease and corticosteroid treatment on calcium metabolism and bone density in children assessed one year after diagnosis, using stable isotopes and dual energy x-ray absorptiometry. J Rheumatol Suppl 58, 38-43.
66. Baker-Le Pain JC, Nakamura MC, Shepherd J, von Scheven E (2011) Assessment of bone remodelling in childhood-onset systemic lupus erythematosus. Rheumatology (Oxford) 50 (3), 611-9.
67. Compeyrot-Lacassagne S, Tyrrell PN, Atenafu E et al. (2007) Prevalence and etiology of low bone mineral density in juvenile systemic lupus erythematosus. Arthritis Rheum 56 (6), 1966-73.
68. Wright TB, Shults J, Leonard MB, Zemel BS, Burnham JM (2009) Hypovitaminosis D is associated with greater body mass index and disease activity in pediatric systemic lupus erythematosus. J Pediatr 155 (2), 260-5.
69. Mok CC, Birmingham DJ, Ho LY, Hebert LA, Song H, Rovin BH (2012) Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q. Lupus 21 (1), 36-42.
70. Robinson AB, Thierry-Palmer M, Gibson KL, Rabinovch CE (2012) Disease activity, proteinuria, and vitamin D status in children with systemic lupus and vitamin D status in children with systemic lupus erythematosus and juvenile dermatomyositis. J Pediatr 160 (2), 297-302.
71. Brunner HI, Silverman ED, To T, Bombardier C, Feldman BM (2002) Risk factors for damage in childhood-onset systemic lupus erythematosus. Arthritis Rheum 46 (2), 436-44.
72. Shaharir S, Ghafor AA, Said MS, Kong MC (2014) A descriptive study of the factors associated with damage in Malaysian patients with lupus nephritis. Lupus 23 (4), 436-42.
73. Huong DL, Amoura Z, Duhaut P et al. (2002) Risk of ovarian failure and fertility after intravenous cyclophosphamide. A study in 84 patients. J Rheumatol 29 (12), 2571-6.
74. Silva CA, Hilario MO, Febronio MV et al. (2007) Risk factors for amenorrhea in juvenile systemic lupus erythematosus (JSLE): a Brazilian multicentre cohort study. Lupus 16 (7), 531-6.
75. Brunner HI, Bishnoi A, Barron AC et al. (2006) Disease outcomes and ovarian function of childhood-onset systemic lupus erythematosus. Lupus 15 (4), 198-206.
76. Silva CA, Hallak J, Pasqualotto FF, Barba MF, Saito MI, Kiss MH (2002) Gonadal function in male adolescents and young males with juvenile onset systemic lupus erythematosus. J Rheumatol 29 (9), 2000-5.
77. Suehiro RM, Borba EF, Bonfa E et al. (2008) Testicular Sertoli cell function in male systemic lupus erythematosus. Rheumatology (Oxford) 47 (11), 1692-7.
78. Dooley MA, Nair R (2008) Therapy Insight: preserving fertility in cyclophosphamide-treated patients with rheumatic disease. Nat Clin Pract Rheumatol 4 (5), 250-7.
79. Nakamura J, Saisu T, Yamashita K, Suzuki C, Kamegaya M, Takahashi K (2010) Age at onset of corticosteroid administration is a risk factor for osteonecrosis in pediatric patients with systemic lupus erythematosus: a prospective magnetic resonance imaging study. Arthritis Rheum 62 (2), 609-15.
80. Yang Y, Kumar S, Silverman ED, Levy DM (2014) Risk factors for symptomatic avascular necrosis in childhood-onset systemic lupus erythematous. Arthritis Rheumatol 66 (S3), S29.
81. Sutton EJ, Davidson JE, Bruce IN (2013) The systemic lupus international collaborating clinics (SLICC) damage index: a systematic literature review. Semin Arthritis Rheum 43 (3), 352-61.
82. Gutiérrez-Suárez R, Ruperto N, Gastaldi R et al. (2006) A proposal for a pediatric version of the systemic lupus international collaborating clinics/American college of rheumatology damage index based on the analysis of 1, 015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 54 (9), 2989-96.